New Cousteau-Linked...
Health Care: Drugs
Achillion Pharmaceuticals Inc. (ACHN: NASDAQ)
$6.95 0.06 | 0.87%
06/04/12 - 02:38 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 6.89 |
| 52 Week High | 12.95 |
| 52 Week Low | 3.81 |
| Avg. Daily Vol. (Mil) | 1.04 |
| Beta (3 year) | 2.19 |
| Share Related Items | |
| Mkt Cap (Mil) | 486.75 |
| Shares Out (Mil) | 70.65 |
| Float (Mil) | 25.35 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.90 |
| Current Ratio | 7.10 |
| LT Debt/ Equity | 0.01 |
| Total Debt / Equity | 0.01 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 182.24 |
| Price/Book | 7.61 |
| Price/Cash Flow | -11.50 |
| Per Share Data | |
| Earnings | -0.65 |
| Sales | 0.04 |
| Book Value | 0.91 |
| Cash Flow | -0.60 |
| Business Summary | |
|---|---|
| Achillion Pharmaceuticals, Inc. is a biopharmaceutical Company which focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. | |
| General Information | |
| 300 George Street
New Haven, CT 06511 |
|
| www.achillion.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 48 | |
| CEO: Michael D. Kishbauch | |
| Short Interest | |
| Current Month (Mil) | 9.87 |
| Previous Month (Mil) | 9.25 |
| Short Interest Ratio (Days) | 7.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -58.40 |
| Return on Investments | -66.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ACHN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- UserThe cash burners
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Hep C Stocks on Wall Str...
- Contributor10 Health-Care Stocks Outpe...
- ContributorHep C Drug Stocks in the Sp...
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
Latest ACHN Headlines from TheStreet
- Grading Hep C Stocks Exiting EASL Confab 04.23.12 | 09:04 am
- Achillion Stock Gaps Down On Today's Open (ACHN) 04.19.12 | 08:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- 8 Stocks Rising on Monster Volume 02.17.12 | 02:02 pm
- Hedge Funds Catch Hep C Fever 02.15.12 | 10:02 am
- Biotech Stock Mailbag: Vical, Hep C Drugs 01.27.12 | 07:01 am
- BioLineRx: Tuesday's Hot Hep C Drug Stock 01.24.12 | 11:01 am
- Idenix Pharma Buyout Likely: Survey 01.20.12 | 03:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- 4 Companies That Are Bleeding Cash 01.13.12 | 07:01 am
Press Releases for ACHN
- Emerald Holds Annual Groundhog Day Investment Forum - Business Wire 02.06.12 | 08:02 am
Partner Headlines for ACHN
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C - Benzinga 04.21.12 | 04:04 pm
- UPDATE: Bank of America Raises Actuant's PT - Benzinga 03.08.12 | 01:03 pm
- Gilead's Electron Data Brings Some Reality Back To The Hep C Market - Seeking Alpha 02.17.12 | 09:02 am
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Company News for January 25, 2012 - Corporate Summary - Zacks 01.25.12 | 10:01 am
- Afternoon Movers; Negative Euro News - Benzinga 01.24.12 | 04:01 pm
- Benzinga's M&A Chatter for Friday January 20, 2012 - Benzinga 01.20.12 | 06:01 pm
- End-of-Day Market Summary for January 20, 2012 - Benzinga 01.20.12 | 04:01 pm
- Afternoon Movers; Markets Moved Sideways - Benzinga 01.20.12 | 04:01 pm
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
